<DOC>
	<DOCNO>NCT02741128</DOCNO>
	<brief_summary>The aim study evaluate safety immunogenicity Dengue vaccine population special interest , HIV-positive adult . Primary Objective : - To describe safety injection CYD dengue vaccine HIV-positive adult . Secondary Objectives : - To describe humoral immune response dengue serotype baseline injection CYD dengue vaccine HIV-positive adult . - To detect CYD dengue vaccinal viremia post-Inj 1 HIV-positive adult . - To describe change CD4 count HIV RNA viral load injection CYD dengue vaccine HIV-positive adult . Observational Objective : - To describe FV ( YF , Dengue ) serological status study population baseline .</brief_summary>
	<brief_title>Safety Immunogenicity Tetravalent Dengue Vaccine HIV-Positive Adults</brief_title>
	<detailed_description>Eligible subject randomize 2:1 ratio 1 2 group receive 3 injection either CYD dengue vaccine placebo 0 , 6 , 12 month . The enrollment subject carry two step , include early safety data review second step . The duration subject 's participation study approximately 18 month .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 50 year day first study vaccination ( study product administration ) ( `` 18 50 '' mean day 18th birthday day 51th birthday ) Inform concent form sign date Able attend schedule visit comply trial procedure Documented seropositivity HIV infection base Brazilian HIV Guidelines ' laboratory criterion ( i.e. , two positive result obtain different independent determination method ) detectable HIV viral load result past Stable HIV condition accord Brazilian HIV Guidelines ( i.e. , CD4 count &gt; 350 cells/mm3 sustainable undetectable HIV viral load [ &lt; 50 copies/mL ] ) least 1 year consent Stable antiretroviral ( ART ) regimen base local HIV protocol least 1 year consent . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation time study enrollment ( 4 week precede first trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination plan receipt vaccine 4 week follow trial vaccination Previous vaccination dengue disease either trial vaccine another vaccine Receipt immune globulin , blood bloodderived product past 3 month Selfreported suspected congenital acquire immunodeficiency , except HIV ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Previous acquire immunodeficiency syndrome ( AIDS ) , define occurrence opportunistic infection last 2 year consent Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) febrile illness ( temperature ≥ 38.0°C ) day vaccination . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study Previous CD4 count &lt; 200 cells/mm3 ( nadir ) since diagnosis HIV History chronic active hepatitis B infection HBsAgpositive History chronic active hepatitis C infection HCV Abpositive Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , urea creatinine &gt; 3 time upper limit normal range ( ULN ) Hemoglobin ( Hb ) &lt; 10 g/dL White blood cell count ( WBC ) &lt; 1500 cells/mm3 Platelets &lt; 100,000 cells/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>CYD Dengue Vaccine</keyword>
</DOC>